Middle East and Africa Biosimilars Market Expected to Grow Significantly by 2035

The biosimilars market in the Middle East and Africa is projected to experience substantial growth over the next decade, driven by several key factors. Patent expirations for existing biologics are creating opportunities for the introduction of biosimilars, while the rising prevalence of chronic diseases is increasing the demand for affordable treatment options.

Regulatory support is also playing a crucial role in this market expansion. As healthcare systems in the region seek to manage costs and improve patient access to medications, biosimilars are becoming an attractive alternative to traditional biologics, particularly for oncological and chronic conditions.

Despite the promising outlook, the market faces challenges, including high development costs and complex regulatory processes that can hinder the entry of new products. Major companies involved in the biosimilars sector include AbbVie, Amgen, Biocon, Celltrion, Dr. Reddy's, Pfizer, Roche, Samsung, Sandoz, Teva, and Viatris, all of which are positioning themselves to capitalize on the growing demand for these therapies.

© 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

Source: KLEA News